• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.一项针对不可切除原发性肝癌患者的基于自体树突状细胞免疫疗法的I期研究。
Cancer Immunol Immunother. 2003 Mar;52(3):155-61. doi: 10.1007/s00262-002-0360-9. Epub 2003 Feb 6.
2
TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.TNF-α 和肿瘤裂解物促进树突状细胞成熟，用于治疗晚期恶性骨和软组织肿瘤的免疫治疗。
PLoS One. 2012;7(12):e52926. doi: 10.1371/journal.pone.0052926. Epub 2012 Dec 21.
3
A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.一项针对晚期肺癌患者，采用源自恶性胸腔积液的自体肿瘤细胞脉冲刺激的树突状细胞进行疫苗接种的试点临床试验。
Cancer. 2005 Feb 15;103(4):763-71. doi: 10.1002/cncr.20843.
4
Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.使用负载癌胚抗原HLA - A24限制性肽的树突状细胞对实体癌进行免疫治疗。
Cancer Immunol Immunother. 2002 Apr;51(2):99-106. doi: 10.1007/s00262-001-0257-z. Epub 2002 Jan 30.
5
Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.自体树突状细胞瘤苗免疫治疗晚期肝癌。
J Cancer Res Clin Oncol. 2013 Jan;139(1):39-48. doi: 10.1007/s00432-012-1298-8. Epub 2012 Aug 12.
6
Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma.用自体放线菌素 D 诱导的黑色素瘤凋亡体冲击的树突状细胞免疫疗法治疗恶性黑色素瘤患者。
Melanoma Res. 2009 Oct;19(5):309-15. doi: 10.1097/cmr.0b013e32832b2717.
7
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.从阳性选择的CD14⁺单核细胞生成树突状细胞用于抗肿瘤免疫治疗。
Leuk Lymphoma. 2004 Jul;45(7):1419-28. doi: 10.1080/10428190310001653682.
8
Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells.由CD34+祖细胞与flt3配体、c-kit配体、粒细胞-巨噬细胞集落刺激因子（GM-CSF）、白细胞介素-4（IL-4）和肿瘤坏死因子-α（TNF-α）生成的树突状细胞是功能性抗原呈递细胞，类似于成熟的单核细胞衍生树突状细胞。
J Immunother. 2000 Jan;23(1):48-58. doi: 10.1097/00002371-200001000-00007.
9
Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.使用单核细胞衍生树突状细胞对多发性骨髓瘤患者进行独特型疫苗接种。
Haematologica. 2003 Oct;88(10):1139-49.
10
Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.用自体肿瘤抗原脉冲处理的自体树突状细胞联合白细胞介素-2对转移性肾细胞癌患者进行疫苗接种：一项1期研究。
J Immunother. 2002 Nov-Dec;25(6):500-8. doi: 10.1097/00002371-200211000-00006.

引用本文的文献

1
Clinical significance of immune cell and biomarker changes in liver cancer.肝癌中免疫细胞和生物标志物变化的临床意义
World J Gastrointest Surg. 2025 Jun 27;17(6):104923. doi: 10.4240/wjgs.v17.i6.104923.
2
Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges.肝细胞癌的免疫治疗与肝移植：当前及未来挑战
World J Transplant. 2025 Jun 18;15(2):98509. doi: 10.5500/wjt.v15.i2.98509.
3
Harnessing Dendritic Cell Function in Hepatocellular Carcinoma: Advances in Immunotherapy and Therapeutic Strategies.利用树突状细胞功能治疗肝细胞癌：免疫疗法及治疗策略的进展
Vaccines (Basel). 2025 May 4;13(5):496. doi: 10.3390/vaccines13050496.
4
The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma.晚期肝细胞癌全身治疗生物标志物的演变格局
Biomark Res. 2025 Apr 12;13(1):60. doi: 10.1186/s40364-025-00774-2.
5
Insights in Molecular Therapies for Hepatocellular Carcinoma.肝细胞癌分子疗法的见解
Cancers (Basel). 2024 May 10;16(10):1831. doi: 10.3390/cancers16101831.
6
The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications.肝细胞癌中肿瘤异质性与免疫逃逸机制的关联及其临床意义。
Br J Cancer. 2024 Aug;131(3):420-429. doi: 10.1038/s41416-024-02684-w. Epub 2024 May 17.
7
Immunotherapy for advanced or recurrent hepatocellular carcinoma.晚期或复发性肝细胞癌的免疫治疗
World J Gastrointest Oncol. 2023 Mar 15;15(3):405-424. doi: 10.4251/wjgo.v15.i3.405.
8
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives.肝细胞癌的免疫治疗：现状与展望。
World J Gastroenterol. 2023 Feb 14;29(6):1054-1075. doi: 10.3748/wjg.v29.i6.1054.
9
Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease.肝细胞癌的免疫疗法：晚期疾病的一种有前景的治疗选择。
World J Hepatol. 2022 Oct 27;14(10):1862-1874. doi: 10.4254/wjh.v14.i10.1862.
10
Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies.基于树突状细胞疫苗的肝细胞癌免疫疗法：临床试验与近期临床前研究
Cancers (Basel). 2022 Sep 8;14(18):4380. doi: 10.3390/cancers14184380.

本文引用的文献

1
Hepatocellular carcinoma: an Asian perspective.肝细胞癌：亚洲视角
Dig Dis. 2001;19(4):263-8. doi: 10.1159/000050692.
2
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.用肿瘤裂解物脉冲处理的树突状细胞对小儿实体瘤患者进行疫苗接种可扩增特异性T细胞并介导肿瘤消退。
Cancer Res. 2001 Dec 1;61(23):8513-9.
3
Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.肿瘤细胞裂解物脉冲处理的人树突状细胞诱导针对胰腺癌细胞的T细胞反应：一种评估肿瘤疫苗的体外模型。
Cancer Res. 2001 Sep 1;61(17):6445-50.
4
Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas.用MAGE肽进行树突状细胞疫苗接种是一种针对胃肠道癌的新型治疗方法。
Clin Cancer Res. 2001 Aug;7(8):2277-84.
5
Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells.用全肿瘤细胞裂解物脉冲树突状细胞诱导针对自体卵巢肿瘤的T细胞反应。
Immunol Invest. 2001 Feb;30(1):33-45. doi: 10.1081/imm-100103689.
6
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection.慢性丙型肝炎病毒感染患者（而非治愈患者）的树突状细胞成熟受损。
Blood. 2001 May 15;97(10):3171-6. doi: 10.1182/blood.v97.10.3171.
7
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.T细胞对源自人甲胎蛋白的HLA-A*0201限制性肽段的反应。
J Immunol. 2001 Apr 15;166(8):5300-8. doi: 10.4049/jimmunol.166.8.5300.
8
Cholangiocarcinoma.胆管癌
Clin Liver Dis. 2001 Feb;5(1):191-218. doi: 10.1016/s1089-3261(05)70161-6.
9
Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells.
Lancet. 2000 Sep 30;356(9236):1163-5. doi: 10.1016/S0140-6736(00)02762-8.
10
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.通过过继性免疫疗法降低肝细胞癌术后复发率：一项随机试验
Lancet. 2000 Sep 2;356(9232):802-7. doi: 10.1016/S0140-6736(00)02654-4.

一项针对不可切除原发性肝癌患者的基于自体树突状细胞免疫疗法的I期研究。

A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer.

作者信息

Iwashita Yukio, Tahara Kouichirou, Goto Shigeru, Sasaki Atsushi, Kai Seiichiro, Seike Masataka, Chen Chao-Long, Kawano Katsunori, Kitano Seigo

机构信息

Department of Surgery I, Oita Medical University, Hasama-machi, Japan.

出版信息

Cancer Immunol Immunother. 2003 Mar;52(3):155-61. doi: 10.1007/s00262-002-0360-9. Epub 2003 Feb 6.

DOI:10.1007/s00262-002-0360-9
PMID:12649744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11032976/
Abstract

BACKGROUND/AIMS: To evaluate the safety and feasibility of immunotherapy based on autologous dendritic cells (DC) for patients with unresectable primary liver cancer (PLC).

METHODS

A total of ten patients were enrolled and immunized with DCs. Autologous DCs were generated ex vivo in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). Cells were then pulsed with tumor lysate (TL), tumor necrosis factor-alpha (TNF-alpha) and keyhole limpet hemocyanin (KLH). Non-adherent cells were collected on day 9 and cells were administered into the inguinal lymph node. Each patient received 1-10 x 10(6) cells four times at weekly intervals.

RESULTS

Immunization was well tolerated in all patients without significant toxicity. DC vaccination induced delayed-type hypersensitivity (DTH) against KLH in seven out of ten patients. In one patient, one of the two liver tumors (tumor in segment 7, 13 mm in diameter) decreased in size to 7 mm and showed necrotic change on computed tomography examination after eight immunizations. In two patients, serum levels of tumor markers decreased after vaccination.

CONCLUSION

The present clinical trial suggested that immunization by TL-pulsed DCs is feasible in patients with unresectable PLC without any toxicity. Further improvement in the clinical results of immunotherapy might be expected by modifying the therapeutic protocol.

摘要

背景/目的：评估基于自体树突状细胞（DC）的免疫疗法对不可切除原发性肝癌（PLC）患者的安全性和可行性。

方法

共纳入10例患者并使用DC进行免疫治疗。在粒细胞-巨噬细胞集落刺激因子（GM-CSF）和白细胞介素-4（IL-4）存在的情况下，在体外生成自体DC。然后用肿瘤裂解物（TL）、肿瘤坏死因子-α（TNF-α）和钥孔戚血蓝蛋白（KLH）对细胞进行脉冲处理。在第9天收集非贴壁细胞，并将细胞注入腹股沟淋巴结。每位患者每周接受4次1-10×10⁶个细胞的治疗。

结果

所有患者对免疫治疗耐受性良好，无明显毒性。DC疫苗接种在10例患者中的7例中诱导了针对KLH的迟发型超敏反应（DTH）。在1例患者中，两个肝肿瘤之一（位于第7段，直径13mm）在8次免疫治疗后，大小缩小至7mm，计算机断层扫描检查显示有坏死改变。在2例患者中，接种疫苗后血清肿瘤标志物水平下降。

结论

目前的临床试验表明，用TL脉冲DC进行免疫治疗在不可切除的PLC患者中是可行的，且无任何毒性。通过修改治疗方案，有望进一步改善免疫治疗的临床效果。